← Leaderboards
Anirban Sen Gupta
Case Western Reserve University
$6,611,792
Attributed
$8,977,323
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2014–24$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$8,977,323 · 3
By mechanism
R01$8,977,323 · 3
Top collaborators
- Matthew D Neal4 shared
- Melanie J. Scott4 shared
- Prithu Sundd4 shared
- Enrico M Novelli1 shared
Most similar at Case Western Reserve University
Same institution · by research overlap
- Louis B. Rice$6,725,418
- Lalitha Nayak$2,646,752
- Alvin H Schmaier$10,124,403
- Amy Wen$47,246
Others in their field
Top investigators on “High Risk”
- Lawrence Corey · Fred Hutchinson Cancer Center$561,333,990
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$424,554,257
- Wafaa M. El-Sadr · Columbia University Health Sciences$337,188,987
- Gary D Acton · University Of California-Davis$320,373,312
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$303,724,352
Research focus
High RiskInjuryIn VitroHemorrhageSiteInnovationMediatingIn VivoBlood PlateletsBindingAcuteSurfacePlasmaIntegrinsPlatelet AggregationTechnologyMimeticsPeptidesFibrinogenCoagulation ProcessDesignMortalityBaseFibrin
Grant awards (17)
Heteromutivalent Peptide-Lipid Nanoconstructs as Artificial Platelet Analogues$522,091
R01 · FY2024 · HL · contact PI
Heteromutivalent Peptide-Lipid Nanoconstructs as Artificial Platelet Analogues$532,746
R01 · FY2023 · HL · contact PI
Mechanisms of platelet exosome-mediated acute chest syndrome in sickle cell disease$775,062
R01 · FY2022 · HL
Heteromutivalent Peptide-Lipid Nanoconstructs as Artificial Platelet Analogues$532,746
R01 · FY2022 · HL · contact PI
Mechanisms of platelet exosome-mediated acute chest syndrome in sickle cell disease$770,088
R01 · FY2021 · HL
Heteromutivalent Peptide-Lipid Nanoconstructs as Artificial Platelet Analogues$563,243
R01 · FY2021 · HL · contact PI
Mechanisms of platelet exosome-mediated acute chest syndrome in sickle cell disease$773,893
R01 · FY2020 · HL
Mechanisms of platelet exosome-mediated acute chest syndrome in sickle cell disease$783,327
R01 · FY2019 · HL
Platelet-inspired Delivery System for Targeted Thrombolytic Therapy$440,494
R01 · FY2018 · HL · contact PI
Heteromultivalent Peptide-Lipid Nanoconstructs as Artificial Platelet Analogs$385,612
R01 · FY2018 · HL · contact PI
Platelet-inspired Delivery System for Targeted Thrombolytic Therapy$442,225
R01 · FY2017 · HL · contact PI
Heteromultivalent Peptide-Lipid Nanoconstructs as Artificial Platelet Analogs$386,166
R01 · FY2017 · HL · contact PI
Platelet-inspired Delivery System for Targeted Thrombolytic Therapy$465,003
R01 · FY2016 · HL · contact PI
Heteromultivalent Peptide-Lipid Nanoconstructs as Artificial Platelet Analogs$386,692
R01 · FY2016 · HL · contact PI
Platelet-inspired Delivery System for Targeted Thrombolytic Therapy$466,440
R01 · FY2015 · HL · contact PI
Heteromultivalent Peptide-Lipid Nanoconstructs as Artificial Platelet Analogs$381,382
R01 · FY2015 · HL · contact PI
Heteromultivalent Peptide-Lipid Nanoconstructs as Artificial Platelet Analogs$370,113
R01 · FY2014 · HL · contact PI